Platelet thromboxane A2 secretion in patients with major depression responsive to electroconvulsive therapy

Erica C. Bruce, Ying Guo, Kathryn C. Lawson, Amita K. Manatunga, S. Freda Auyeung, William M. McDonald, Natasha Rushing, Angelo R. Brown, Natalie Gilles, Milburn Emery, Robert Bonsall, Jocelyn Porquez, Zachary Stowe, Charles Nemeroff, Dominique Musselman

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

OBJECTIVE: To determine a) whether clinical response to electroconvulsive therapy (ECT) is associated with decreased platelet activation in patients with major depressive disorder (MDD) and b) if any medical/demographic characteristics predict response to ECT or changes in platelet activation. Increased platelet activation may underlie the increased risk of coronary artery disease (CAD) in patients with MDD. METHODS: Before their first and sixth ECT treatments, study patients (n = 44) completed the Beck Depression Inventory (BDI) to assess the severity of depressive symptoms. Activity of the platelet thromboxane (TBX) A2 pathway was assessed by measuring the morning spot urinary concentrations of 11-dehydroxy-thromboxane B2 (11-D-TBX B2), a major metabolite of platelet-derived TBX A2. RESULTS: Multivariate logistic regression analyses revealed that improvement on the BDI was significantly more likely in patients without a history of hypertension (p = .02) and in patients who were prescribed a greater number of "platelet-altering" medications (p = .03). During a course of ECT, a decrease in urinary 11-D-TBX B2 was significantly more likely to occur in ECT nonresponders (p = .01) and younger patients (p = .02). CONCLUSIONS: Clinical response to ECT coadministered may not be associated with decreases in platelet-derived TBX. Future studies will confirm which somatic "antidepression" treatments offer optimal thrombovascular benefits for depressed patients with multiple risk factors for, or clinically evident, cerebral disease or CAD.

Original languageEnglish
Pages (from-to)319-327
Number of pages9
JournalPsychosomatic Medicine
Volume70
Issue number3
DOIs
StatePublished - Apr 1 2008
Externally publishedYes

Fingerprint

Thromboxane A2
Electroconvulsive Therapy
Blood Platelets
Depression
Thromboxane B2
Platelet Activation
Major Depressive Disorder
Coronary Artery Disease
Equipment and Supplies
Thromboxanes
Platelet Count
Logistic Models
Regression Analysis
Demography
Hypertension
Therapeutics

Keywords

  • Antidepressants
  • Autocrine pathways
  • Electroconvulsive therapy
  • Major depressive disorder
  • Platelet function
  • Thromboxane

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Psychology(all)

Cite this

Platelet thromboxane A2 secretion in patients with major depression responsive to electroconvulsive therapy. / Bruce, Erica C.; Guo, Ying; Lawson, Kathryn C.; Manatunga, Amita K.; Auyeung, S. Freda; McDonald, William M.; Rushing, Natasha; Brown, Angelo R.; Gilles, Natalie; Emery, Milburn; Bonsall, Robert; Porquez, Jocelyn; Stowe, Zachary; Nemeroff, Charles; Musselman, Dominique.

In: Psychosomatic Medicine, Vol. 70, No. 3, 01.04.2008, p. 319-327.

Research output: Contribution to journalArticle

Bruce, EC, Guo, Y, Lawson, KC, Manatunga, AK, Auyeung, SF, McDonald, WM, Rushing, N, Brown, AR, Gilles, N, Emery, M, Bonsall, R, Porquez, J, Stowe, Z, Nemeroff, C & Musselman, D 2008, 'Platelet thromboxane A2 secretion in patients with major depression responsive to electroconvulsive therapy', Psychosomatic Medicine, vol. 70, no. 3, pp. 319-327. https://doi.org/10.1097/PSY.0b013e3181663580
Bruce, Erica C. ; Guo, Ying ; Lawson, Kathryn C. ; Manatunga, Amita K. ; Auyeung, S. Freda ; McDonald, William M. ; Rushing, Natasha ; Brown, Angelo R. ; Gilles, Natalie ; Emery, Milburn ; Bonsall, Robert ; Porquez, Jocelyn ; Stowe, Zachary ; Nemeroff, Charles ; Musselman, Dominique. / Platelet thromboxane A2 secretion in patients with major depression responsive to electroconvulsive therapy. In: Psychosomatic Medicine. 2008 ; Vol. 70, No. 3. pp. 319-327.
@article{4e79193e1c004436978b58ab5526dcd0,
title = "Platelet thromboxane A2 secretion in patients with major depression responsive to electroconvulsive therapy",
abstract = "OBJECTIVE: To determine a) whether clinical response to electroconvulsive therapy (ECT) is associated with decreased platelet activation in patients with major depressive disorder (MDD) and b) if any medical/demographic characteristics predict response to ECT or changes in platelet activation. Increased platelet activation may underlie the increased risk of coronary artery disease (CAD) in patients with MDD. METHODS: Before their first and sixth ECT treatments, study patients (n = 44) completed the Beck Depression Inventory (BDI) to assess the severity of depressive symptoms. Activity of the platelet thromboxane (TBX) A2 pathway was assessed by measuring the morning spot urinary concentrations of 11-dehydroxy-thromboxane B2 (11-D-TBX B2), a major metabolite of platelet-derived TBX A2. RESULTS: Multivariate logistic regression analyses revealed that improvement on the BDI was significantly more likely in patients without a history of hypertension (p = .02) and in patients who were prescribed a greater number of {"}platelet-altering{"} medications (p = .03). During a course of ECT, a decrease in urinary 11-D-TBX B2 was significantly more likely to occur in ECT nonresponders (p = .01) and younger patients (p = .02). CONCLUSIONS: Clinical response to ECT coadministered may not be associated with decreases in platelet-derived TBX. Future studies will confirm which somatic {"}antidepression{"} treatments offer optimal thrombovascular benefits for depressed patients with multiple risk factors for, or clinically evident, cerebral disease or CAD.",
keywords = "Antidepressants, Autocrine pathways, Electroconvulsive therapy, Major depressive disorder, Platelet function, Thromboxane",
author = "Bruce, {Erica C.} and Ying Guo and Lawson, {Kathryn C.} and Manatunga, {Amita K.} and Auyeung, {S. Freda} and McDonald, {William M.} and Natasha Rushing and Brown, {Angelo R.} and Natalie Gilles and Milburn Emery and Robert Bonsall and Jocelyn Porquez and Zachary Stowe and Charles Nemeroff and Dominique Musselman",
year = "2008",
month = "4",
day = "1",
doi = "10.1097/PSY.0b013e3181663580",
language = "English",
volume = "70",
pages = "319--327",
journal = "Psychosomatic Medicine",
issn = "0033-3174",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Platelet thromboxane A2 secretion in patients with major depression responsive to electroconvulsive therapy

AU - Bruce, Erica C.

AU - Guo, Ying

AU - Lawson, Kathryn C.

AU - Manatunga, Amita K.

AU - Auyeung, S. Freda

AU - McDonald, William M.

AU - Rushing, Natasha

AU - Brown, Angelo R.

AU - Gilles, Natalie

AU - Emery, Milburn

AU - Bonsall, Robert

AU - Porquez, Jocelyn

AU - Stowe, Zachary

AU - Nemeroff, Charles

AU - Musselman, Dominique

PY - 2008/4/1

Y1 - 2008/4/1

N2 - OBJECTIVE: To determine a) whether clinical response to electroconvulsive therapy (ECT) is associated with decreased platelet activation in patients with major depressive disorder (MDD) and b) if any medical/demographic characteristics predict response to ECT or changes in platelet activation. Increased platelet activation may underlie the increased risk of coronary artery disease (CAD) in patients with MDD. METHODS: Before their first and sixth ECT treatments, study patients (n = 44) completed the Beck Depression Inventory (BDI) to assess the severity of depressive symptoms. Activity of the platelet thromboxane (TBX) A2 pathway was assessed by measuring the morning spot urinary concentrations of 11-dehydroxy-thromboxane B2 (11-D-TBX B2), a major metabolite of platelet-derived TBX A2. RESULTS: Multivariate logistic regression analyses revealed that improvement on the BDI was significantly more likely in patients without a history of hypertension (p = .02) and in patients who were prescribed a greater number of "platelet-altering" medications (p = .03). During a course of ECT, a decrease in urinary 11-D-TBX B2 was significantly more likely to occur in ECT nonresponders (p = .01) and younger patients (p = .02). CONCLUSIONS: Clinical response to ECT coadministered may not be associated with decreases in platelet-derived TBX. Future studies will confirm which somatic "antidepression" treatments offer optimal thrombovascular benefits for depressed patients with multiple risk factors for, or clinically evident, cerebral disease or CAD.

AB - OBJECTIVE: To determine a) whether clinical response to electroconvulsive therapy (ECT) is associated with decreased platelet activation in patients with major depressive disorder (MDD) and b) if any medical/demographic characteristics predict response to ECT or changes in platelet activation. Increased platelet activation may underlie the increased risk of coronary artery disease (CAD) in patients with MDD. METHODS: Before their first and sixth ECT treatments, study patients (n = 44) completed the Beck Depression Inventory (BDI) to assess the severity of depressive symptoms. Activity of the platelet thromboxane (TBX) A2 pathway was assessed by measuring the morning spot urinary concentrations of 11-dehydroxy-thromboxane B2 (11-D-TBX B2), a major metabolite of platelet-derived TBX A2. RESULTS: Multivariate logistic regression analyses revealed that improvement on the BDI was significantly more likely in patients without a history of hypertension (p = .02) and in patients who were prescribed a greater number of "platelet-altering" medications (p = .03). During a course of ECT, a decrease in urinary 11-D-TBX B2 was significantly more likely to occur in ECT nonresponders (p = .01) and younger patients (p = .02). CONCLUSIONS: Clinical response to ECT coadministered may not be associated with decreases in platelet-derived TBX. Future studies will confirm which somatic "antidepression" treatments offer optimal thrombovascular benefits for depressed patients with multiple risk factors for, or clinically evident, cerebral disease or CAD.

KW - Antidepressants

KW - Autocrine pathways

KW - Electroconvulsive therapy

KW - Major depressive disorder

KW - Platelet function

KW - Thromboxane

UR - http://www.scopus.com/inward/record.url?scp=42149147869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42149147869&partnerID=8YFLogxK

U2 - 10.1097/PSY.0b013e3181663580

DO - 10.1097/PSY.0b013e3181663580

M3 - Article

VL - 70

SP - 319

EP - 327

JO - Psychosomatic Medicine

JF - Psychosomatic Medicine

SN - 0033-3174

IS - 3

ER -